MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-15-2026
Kala Pharmaceuticals General and Administrative Expenses 2011-2026 | KALA
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Kala Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23.6 M | 18.3 M | 20.6 M | 65 M | 105 M | 81.1 M | 65 M | 35.4 M | 10.9 M | 7.64 M | 4.61 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 105 M | 4.61 M | 39.8 M |
Quarterly General and Administrative Expenses Kala Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.53 M | 4.64 M | 4.59 M | - | 4.4 M | 4.32 M | 5.42 M | - | 4.95 M | 4.96 M | 6.03 M | - | 9.55 M | 22.7 M | 27 M | - | 25.3 M | 28 M | 27.7 M | - | 23.9 M | 15.3 M | 15.4 M | - | 15.3 M | 17 M | 18.2 M | - | 8.47 M | 7.15 M | 5.48 M | - | 2.52 M | 1.56 M | 1.53 M | - | 1.49 M | 3.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 28 M | 1.49 M | 11.1 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M |  Germany |
 |
AgeX Therapeutics
AGE
|
11 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
900 M | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
16.2 M | - | 2.54 % | $ 160 B | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | USA |
 |
Esperion Therapeutics
ESPR
|
166 M | $ 3.13 | 0.16 % | $ 651 M | USA |
 |
Exelixis
EXEL
|
519 M | $ 46.2 | 4.01 % | $ 12.5 B | USA |
 |
Athira Pharma
ATHA
|
16.7 M | - | - | $ 269 M | USA |
 |
Fortress Biotech
FBIO
|
96.4 M | $ 2.49 | 1.22 % | $ 69.5 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
28.3 M | $ 6.85 | 1.93 % | $ 196 M | USA |
 |
Galectin Therapeutics
GALT
|
5.8 M | $ 2.28 | 2.24 % | $ 146 M | USA |
 |
Galapagos NV
GLPG
|
141 M | $ 28.82 | 1.51 % | $ 2.69 B |  Belgium |
 |
Grifols, S.A.
GRFS
|
1.06 B | $ 8.4 | 1.51 % | $ 6.83 B |  Spain |
 |
Genprex
GNPX
|
6.09 M | $ 0.89 | 0.28 % | $ 830 K | USA |
 |
BioNTech SE
BNTX
|
286 M | $ 94.21 | -1.35 % | $ 27.2 B | Germany |
 |
InflaRx N.V.
IFRX
|
12 M | $ 2.37 | 20.05 % | $ 152 M | Germany |
 |
Immuron Limited
IMRN
|
3.52 M | $ 0.82 | 3.97 % | $ 6.82 M |  Australia |
 |
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
15.7 M | - | - | $ 231 M | USA |
 |
Ionis Pharmaceuticals
IONS
|
394 M | $ 76.34 | 1.45 % | $ 12.2 B | USA |
 |
Innate Pharma S.A.
IPHA
|
25.5 M | $ 1.49 | 3.83 % | $ 235 M | France |
 |
INmune Bio
INMB
|
10.3 M | $ 1.51 | -1.95 % | $ 37.4 M | USA |
 |
Kamada Ltd.
KMDA
|
12.6 M | $ 8.31 | 1.22 % | $ 260 M |  Israel |
 |
Kymera Therapeutics
KYMR
|
68.2 M | $ 85.92 | 3.88 % | $ 7.26 B | USA |
 |
Kazia Therapeutics Limited
KZIA
|
4.51 M | $ 12.98 | -3.53 % | $ 1.72 B | Australia |
 |
ACADIA Pharmaceuticals
ACAD
|
488 M | $ 23.02 | 2.98 % | $ 3.81 B | USA |
 |
Liquidia Corporation
LQDA
|
157 M | $ 41.73 | 3.97 % | $ 3.59 B | USA |
 |
Advaxis
ADXS
|
12.2 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.66 M | $ 3.56 | 1.71 % | $ 5.86 M | Israel |
 |
Aeterna Zentaris
AEZS
|
5.92 M | - | 5.93 % | $ 314 M |  Canada |
 |
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
257 M | $ 106.77 | 0.9 % | $ 5.36 B | USA |
 |
CureVac N.V.
CVAC
|
100 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | USA |
 |
MannKind Corporation
MNKD
|
144 M | $ 3.88 | 35.49 % | $ 1.19 B | USA |
 |
AIkido Pharma
AIKI
|
23.8 M | - | 1.93 % | $ 17.4 M | USA |
 |
Mereo BioPharma Group plc
MREO
|
21.2 M | $ 0.27 | -3.84 % | $ 660 M | Britain |
 |
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
13.4 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
19.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
22.2 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
69.6 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
45.1 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
11 M | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
275 M | $ 23.63 | 0.9 % | $ 3.01 B | USA |
 |
Nanobiotix S.A.
NBTX
|
19.4 M | $ 39.36 | 13.2 % | $ 286 B | France |
 |
Allena Pharmaceuticals
ALNA
|
12.7 M | - | 3.16 % | $ 1.9 M | USA |